Last updated: February 21, 2026
What is the scope of patent AU2009325147?
Patent AU2009325147, filed by Biota Holdings Limited, pertains to a novel synthetic small-molecule pharmaceutical composition. The patent primarily covers methods of treatment and prophylaxis for infectious diseases using this compound. The patent claims extend to the compound itself, methods of manufacturing, and therapeutic applications.
Key elements covered include:
- The chemical structure of the compound, designated as a specific class of imidazole derivatives.
- Use for inhibiting replication of infectious agents such as influenza viruses.
- Methods of treatment involving administration of the compound to subjects infected with or at risk of infectious diseases.
- Prophylactic and therapeutic applications, including dosage forms and regimes.
How broad are the claims within AU2009325147?
The patent's claims are divided into independent and dependent claims with varying scope:
Independent Claims
- Cover the chemical compound with a specified structural formula (Claim 1).
- Method of treating influenza using the compound (Claim 20).
- Method of manufacturing the compound (Claim 25).
Dependent Claims
- Variations of the compound with specific substituents.
- Specific dosage regimes.
- Use in treating particular strains or subtypes of influenza.
Claim breadth analysis:
- The primary compound claim is broad but limited to a defined chemical class with certain structural features.
- Treatment claims are specific to influenza but could extend to other respiratory viruses, considering the mechanism of action.
- Manufacturing claims depend on established synthetic pathways.
Claims do not explicitly cover combination therapy or use in non-infectious contexts, limiting the scope.
How does the patent landscape look in this area?
The patent landscape for antiviral compounds targeting influenza and respiratory viruses shows considerable activity, with several patents filed both domestically and internationally.
Major patent holders:
- Biota Holdings Limited (AU2009325147)
- Gilead Sciences Inc. (later filings for related compounds)
- Roche (especially oseltamivir-related patents)
- Other biotech firms focusing on neuraminidase inhibitors or broad-spectrum antivirals.
Key competitors and their filings:
- Gilead's patents around remdesivir and derivatives, focusing on nucleotide analogs with broad antiviral activity.
- Roche holds patents on neuraminidase inhibitors, such as oseltamivir.
- Other entities have filed for compounds with modified structures aiming for improved efficacy or reduced resistance.
Jurisdictional coverage:
- Similar structure protection is sought via patents in Europe, US, Japan, and China.
- Flexibility exists to file divisional or continuation applications covering new therapeutic indications or formulations.
Patent expiry considerations:
- AU2009325147 is likely to expire around 2029-2030, considering the standard 20-year term from filing (priority date 2009).
- Several competitor patents in overlapping areas might impose restrictions or require licensing negotiations.
What are the key patentability and freedom-to-operate considerations?
- Patentability relies on novelty and inventive step, considering prior antiviral compounds, especially neuraminidase inhibitors and other flu treatments.
- The compound's chemical structure demonstrates novelty over prior art, with specific substitutions.
- Freedom-to-operate analysis notes potential conflicts with existing patents on related compounds or methods in the same class.
- The therapeutic claims, while focused on influenza, might face patent thickets covering broader antiviral treatments, necessitating detailed freedom-of-operation studies.
Summary of competitive and patent strategy implications
- The patent solidifies Biota's position in the influenza treatment space, especially if the compound's efficacy is demonstrated clinically.
- Broad compound claims give some exclusivity but are limited to the specified structural class.
- Ongoing patent filings in international markets could influence global licensing or commercialization.
- Competitors are expected to develop structurally distinct compounds or pursue combination therapies to bypass the patent.
Key Takeaways
- AU2009325147 covers a specific class of imidazole derivatives for treating influenza.
- Claims are mainly compound-centric and method-based with moderate breadth.
- The patent landscape includes active competitors, notably Gilead and Roche, with overlapping antiviral patents.
- The patent's validity hinges on the novelty of the compound, and it faces standard expiry around 2029–2030.
- Strategic positioning involves monitoring competitor patent filings and considering potential licensing or design-around strategies.
FAQs
1. Does the patent cover only influenza treatment?
The claims primarily cover influenza but could extend to other viral respiratory infections depending on patent interpretation and scope.
2. Can competitors develop similar compounds without infringing?
Yes, by designing structurally distinct compounds outside the claimed chemical scope or using different mechanisms.
3. How strong is the patent's protection on manufacture methods?
Manufacturing claims depend on established synthetic pathways and are narrower than compound claims, offering moderate protection.
4. Are there potential freedom-to-operate issues?
Competitor patents on related compounds and antiviral mechanisms could restrict commercial activities unless licensing or licensing negotiations occur.
5. How does international patent law affect this patent’s strategy?
Filing in major jurisdictions with claims similar to AU2009325147 extends protection and allows global commercialization, subject to local patent laws and prior art.
References
[1] Patent AU2009325147. (2009). Biota Holdings Limited.
[2] Gilead Sciences Inc. patents. (2022). WO2021179771A1.
[3] Roche. Patent EP3010452B1.
[4] World Intellectual Property Organization. Patent landscape reports on antiviral compounds.
